Grail, an American biotech company, mistakenly (or not) informed its patients that they had cancer, even those who had never donated blood for testing. Grail is developing an innovative test for the early detection of cancer and was preparing to present its product at a major cancer conference in the coming days.
More than 400 patients of the US biotech startup Grail have received letters from the company that they have cancer. As it turned out, the letters were sent “by mistake,” writes the Financial Times. It is noteworthy that even patients who had never donated blood to the Grail for testing were told they had cancer.
The email was a software bug that was quickly fixed, the newspaper said. Patients who received the letter were contacted within 36 hours and explained the situation.
Grail is developing an innovative test for the early detection of cancer. The company says its product will detect more than 50 types of cancer with a single blood test. A recent trial on 6,000 patients showed “promising results,” the newspaper said.
The startup was to present its trial at a major cancer trade show this weekend in the US, but has postponed the plans, notes the Financial Times. Investors and insurers have also questioned his plans to work with Grail.
Author:
Kirill Bilyk
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
